Probable ATP-dependent RNA helicase DHX34 (DHX34)

Probable ATP-dependent RNA helicase DHX34 (DHX34) is an enzyme from the DExH/D box family of RNA helicases that uses ATP hydrolysis to drive changes in RNA and protein-RNA complexes[1][2][3]. DHX34 is a central factor in the nonsense-mediated mRNA decay (NMD) surveillance pathway, where it is recruited to the NMD machinery and promotes a transition from the initial surveillance complex (SURF) to the decay-inducing complex (DECID), enabling phosphorylation of UPF1 and degradation of aberrant mRNAs with premature stop codons[1][3][4]. In addition, DHX34 serves as a regulator of pre-mRNA alternative splicing, binding to pre-mRNAs near exon–intron boundaries and influencing spliceosome function[2]. Mutations compromising DHX34 function have been linked to familial predisposition to myelodysplasia/acute myeloid leukemia in humans, partially due to dysregulation of splicing and defective NMD[2]. DHX34 is therefore implicated in both RNA quality control and hematopoietic differentiation, with emerging relevance to cancer and other diseases[2]. There are currently no known therapeutic drugs that target DHX34 directly.

Other names

DExH-box helicase 34DEAH box protein 34DDX34KIAA0134DEAH (Asp-Glu-Ala-His) box polypeptide 34ATP-dependent RNA helicase DHX34DExH/D box helicase 34